A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI

doi:10.1111/jcmm.16886

機構典藏 > College of Sciences > Doctoral Program in Applied Science > Journal Article > Item 987654321/121477

Please use this identifier to cite or link to this item: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/121477

Title:	A novel naphthalimide derivative reduces platelet activation and thrombus formation via suppressing GPVI
Authors:	Shih, Tzenge-Lien;Lin, Kuan-Hung;Chen, Ray-Jade;Chen, Ting-Yu;Kao, Wei-Ting;Liu, Jen-Wei;Wang, Hsueh-Hsiao;Peng, Hsien-Yu;Sun, Yu-Yo;Lu, Wan-Jung
Date:	2021-08-27
Issue Date:	2021-10-14 12:12:15 (UTC+8)
Publisher:	Wiley-Blackwell Publishing Ltd.
Abstract:	Naphthalimide derivatives have multiple biological activities, including antitumour and anti-inflammatory activities. We previously synthesized several naphthalimide derivatives; of them, compound 5 was found to exert the strongest inhibitory effect on human DNA topoisomerase II activity. However, the effects of naphthalimide derivatives on platelet activation have not yet been investigated. Therefore, the mechanism underlying the antiplatelet activity of compound 5 was determined in this study. The data revealed that compound 5 (5–10 μM) inhibited collagen- and convulxin- but not thrombin- or U46619-mediated platelet aggregation, suggesting that compound 5 is more sensitive to the inhibition of glycoprotein VI (GPVI) signalling. Indeed, compound 5 could inhibit the phosphorylation of signalling molecules downstream of GPVI, followed by the inhibition of calcium mobilization, granule release and GPIIb/IIIa activation. Moreover, compound 5 prevented pulmonary embolism and prolonged the occlusion time, but tended to prolong the bleeding time, indicating that it can prevent thrombus formation but may increase bleeding risk. This study is the first to demonstrate that the naphthalimide derivative compound 5 exerts antiplatelet and antithrombotic effects. Future studies should modify compound 5 to synthesize more potent and efficient antiplatelet agents while minimizing bleeding risk, which may offer a therapeutic potential for cardiovascular diseases.
Relation:	Journal of Cellular and Molecular Medicine 25(19), p.9434-9446
DOI:	10.1111/jcmm.16886
Appears in Collections:	[Doctoral Program in Applied Science] Journal Article

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	171	View/Open

Loading...